Postmenopausal osteoporosis and hormone replacement therapy.

Area of Science:

• Endocrinology
• Gerontology
• Bone Biology

Background:

• Osteoporosis is a significant skeletal disease marked by low bone mass and deterioration, increasing fracture risk.
• Postmenopausal osteoporosis, driven by estrogen deficiency, poses a major public health challenge.
• Hormone replacement therapy (HRT) is a traditional, effective intervention for preventing osteoporotic fractures in postmenopausal women.

Purpose of the Study:

• To evaluate the efficacy of low-dose hormone replacement therapy (LD-HRT) in preventing postmenopausal osteoporosis.
• To compare the bone-sparing effects of LD-HRT with standard-dose HRT.
• To explore LD-HRT's potential for improving long-term patient adherence and managing menopausal symptoms.

Main Methods:

• Review of studies assessing standard-dose HRT (e.g., 0.625 mg conjugated equine estrogen, 2 mg micronized estradiol) and percutaneous 17 beta-estradiol.
• Analysis of research comparing LD-HRT with standard-dose HRT for osteoporosis prevention.
• Examination of data on HRT's long-term impact on bone health and fracture risk across different menopausal stages.

Main Results:

• Estrogenic effects on bone are dose-dependent, with established doses preventing bone loss.
• HRT demonstrates effectiveness in preventing bone loss throughout postmenopausal life, with benefits most pronounced shortly after menopause.
• LD-HRT shows promise in maintaining bone protection and controlling menopausal symptoms, potentially enhancing patient compliance.

Conclusions:

• Long-term or lifelong estrogen therapy is crucial for sustained bone health benefits in postmenopausal women.
• LD-HRT presents a strategy to mitigate side effects associated with higher HRT doses, improving treatment continuation.
• Personalized dosing of LD-HRT can optimize osteoporosis management and menopausal symptom control for individual patients.